Immunotech Biopharm Ltd
Company Profile
Business description
Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company in China. The company is focused on the research, development, and commercialization of T-cell immunotherapy. Its product EAL is a multi-target cellular immunotherapy product for the treatment of various types of cancer. Its product pipeline features classes of cellular immunotherapy products, including both non-genetically modified and genetically modified products, as well as both multi-target and single-target products. Its other products include the CAR-T cell series and the TCR-T cell series.
Contact
No.1 Kangding Street
8th Floor, Block 1, Guosheng Technology Park
Beijing Economic-technological Development Area
Beijing100176
CHNT: +86 8610884002
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
173
Stocks News & Analysis
stocks
Procter & Gamble earnings: Frigid sales and margins don’t suggest cracks in its standing
stocks
Our view on Santos after production is ramped up
stocks
GE Aerospace earnings: No good deed goes unpunished
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,210.70 | 36.50 | 0.40% |
| CAC 40 | 8,148.89 | 79.72 | 0.99% |
| DAX 40 | 24,856.47 | 295.49 | 1.20% |
| Dow JONES (US) | 49,384.01 | 306.78 | 0.63% |
| FTSE 100 | 10,150.05 | 11.96 | 0.12% |
| HKSE | 26,797.07 | 167.11 | 0.63% |
| NASDAQ | 23,436.02 | 211.20 | 0.91% |
| Nikkei 225 | 53,851.87 | 162.98 | 0.30% |
| NZX 50 Index | 13,498.57 | 58.30 | -0.43% |
| S&P 500 | 6,913.35 | 37.73 | 0.55% |
| S&P/ASX 200 | 8,880.30 | 35.20 | 0.40% |
| SSE Composite Index | 4,136.46 | 13.88 | 0.34% |